#USA #New York #Lipocine #LPCN #Oral Therapeutics

Lipocine Inc. to Present at H.C. Wainwright Conference

Lipocine Inc. (NASDAQ: LPCN), a leader in specialty pharmaceuticals focused on innovative oral therapeutics, has announced its participation in the upcoming H.C. Wainwright 28th Annual Global Investment Conference. Taking place from September 14 to 16, 2026, this prestigious event will be held both in-person in New York City and virtually, enabling broader access for investors.

Presentation Schedule

Lipocine's management team is scheduled to present on Wednesday, September 16, 2026, at 10 AM ET. During this presentation, they will discuss the company's strategic direction and advancements in their therapeutic pipeline, which is designed to address significant unmet medical needs.

Investors looking to attend the conference can easily register through the provided link. For those interested in deeper engagement, Lipocine encourages arranging one-on-one meetings with their representatives via H.C. Wainwright, fostering opportunities for more personalized discussions.

Accessing the Presentation

For those unable to attend live, Lipocine has ensured that the presentation will be accessible through a live webcast, available in the Events section of their corporate website. The recording will be archived for 90 days, allowing interested parties to revisit the insights shared during the session.

About Lipocine Inc.

Lipocine is committed to revolutionizing the delivery of therapeutics through their proprietary platform, focusing on the oral administration of their innovative drug candidates. The company is developing several promising candidates aimed at treating a range of conditions, including:

• - LPCN 1154: Targeted for the treatment of postpartum depression.
• - LPCN 2201: Designed for managing major depressive disorder.
• - LPCN 2101: Under development for epilepsy.
• - LPCN 2203: Targeted towards essential tremor management.
• - LPCN 2401: Aiding in obesity management and improved body composition.
• - LPCN 1148: Focused on liver cirrhosis management.
• - LPCN 1107: A candidate for preventing preterm birth.

Additionally, TLANDO, Lipocine's innovative oral prodrug of testosterone, is already FDA-approved for treating hypogonadism in adult males.

As a biopharmaceutical company, Lipocine strives to create a favorable risk-benefit profile for its products, ensuring that they address large market needs while offering patient-friendly delivery options. The company's existing pipeline highlights its dedication to research and development, aiming to bring forward the next generation of oral therapeutics that can significantly improve patient outcomes.

Looking Ahead

With numerous candidates in various stages of development and ongoing efforts to secure potential partnerships, the future looks promising for Lipocine. The upcoming investment conference represents a strategic opportunity for Lipocine to strengthen its visibility, communicate its innovations, and foster relationships with potential investors who align with their mission.

For more information about their research endeavors and product offerings, visit www.lipocine.com.